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• Synthesis of a range of 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo [1,2-c] 
thiazoles (PT)
• In vitro cytotoxicity of PTs on human breast cancer cell lines was evaluated
• The effects of two promising compounds on cancer biology was studied In an effort to produce new structures with better anticancer activity and that may give additional knowledge on SAR, based on structure 3, we synthesized and evaluated the effect of replacing the phenyl substituent at C-3 by a 4-methoxyphenyl group 9a and by the more hydrophilic 4-hydroxyphenyl group 9b. The 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole 12, derived from penicillamine, has also been studied in order to determine whether the presence of two methyl groups at C-1 would lead to enhance cytotoxic activity. The new compounds were assayed for their in vitro cytotoxicity on several human breast cancer cell lines, including TN breast cancer cell lines.
So far our studies were limited to cytotoxicity of the compounds synthesized. However, to understand the mechanism of action and the effects on cancer biology further studies were needed.
Therefore, we evaluated the effects of two promising compounds on cell survival, viability, cell cycle, DNA damage and expression of proteins related to cell death pathways. 
Results and Discussion

Chemistry
Biological evaluation 2.2.1 In vitro antiproliferative activities and SAR
The new compounds were evaluated for their in vitro anti-proliferative activity against human breast cancer representative of HER2 + (HCC1954), RH + (MCF7) and TN (HCC1806) tumors (Table   1 ). In the HCC1954 cell line none of the compounds affect cell proliferation at 24 h of incubation.
However, when cells were incubated for 48 h with the studied compounds a significant decrease in IC 50 values was observed (3, 9a and 9b p<0.001; 6 p=o.019; 12 p=0.017). 3 is the most promising anti-proliferative compound against HCC1954 cells and the less promising is 9a. In the MCF7 cell line, 3 and 6 are the most promising compounds concerning anti-proliferative activity with IC 50 values of 0.6 µM and 0.3 µM, respectively, for 96 h incubation time. On the other hand, 12 showed no anti-proliferative activity against MCF7 cell line, in the concentrations tested, up to 100 µM.
Despite the fact that 9a and 9b showed moderate anti-proliferative activity in MCF7 cell line, the decreasing IC 50 value over time has statistical significance (p<0.05). In the HCC1806 cell line, 9b is the most promising compound with significant decrease of IC 50 value over time (p<0.05), with IC 50 value of 5.4 µM for 96 h incubation time. All the other compounds showed a significant decrease in the IC 50 value going from 24 h to 48 h incubation time (p<0.001), being 3 and 6 the less active compounds in this cell line.
The design of new compounds has been guided considering 3 as the lead compound [5] and the structural modifications were thought not only to obtain derivatives with higher anti-proliferation
activity, but also to gather data regarding SAR. We showed that the presence of the phenyl group at C-3 seemed to be important to the activity of the compounds [5] Regarding MCF7 cell line the new derivatives show lower activity than the lead compound 3.
However, these compounds presented better anti-cancer activity than 1H,3H-pyrrolo[1,2-c]thiazole 3, against TN cell line, HCC1806, which is more challenging to treat and lack a targeted therapy.
Particularly interesting were the results obtained for 4-hydroxyphenyl substituted derivative 9b, which prove to be the most promising compound regarding HCC1806 cell line, a TN-breast cancer.
So far, all the compounds studied in our group were unsubstituted at C-1. Thus, 1,1-dimethyl-1H,3H-pyrrolo[1,2-c]thiazole 12 was synthesized and its biological evaluation as anticancer activity against HCC1806, HCC1954 and MCF7 breast cancer human cell lines was carried out (Table 1) .
However, the IC 50 values obtained for 12 were rather high in comparison with other studied compounds. Thus, from current and previous results, we can conclude that substitution at C-1 by methyl groups does not improve anti-cancer activity of 1H,3H-pyrrolo[1,2-c]thiazole derivatives.
Moreover, 12 has the S absolute configuration at C-3, which potentiates cytotoxic activity against MCF7 cell line, as we already discussed. These results indicate that the substitution pattern in the pyrrolo[1,2-c]thiazole ring system plays a more significant role in the anti-proliferative activity than the absolute configuration at C-3.
Cell cultures are sensitive to treatment
Since 1H,3H-pyrrolo[1,2-c]thiazoles 3 and 9b are promising due to their anti-proliferative activity against HR + MCF7 cell line and TN HCC1806 cell lines, we tested the long-term sensitivity and survival of a cell culture to the treatment performing the clonogenic assay. As we can observe in Figure 2 , all treatments reduces significantly (p<0.001) the surviving factor of both cell cultures. It is further noticed that HCC1806 cell line is particularly sensitive to treatment since surviving factor is below 2%.
These results show that HCC1806 cell line in particular presents high sensitivity to chemotherapy with these compounds, proving that this cell line presents a BRCAness phenotype. It is further noticed that treatment with 3, which is the compound that presents the higher IC 50 value, is the one that most affects HCC1806 survival.
Cell mass and total protein production is reduced
The total protein content was analyzed after treatment of MCF7 and HCC1806 cell lines with 1H,3H-pyrrolo[1,2-c]thiazoles 3 and 9b ( Figure 3 ). HCC1806 cell line reduces the total protein content to about 50% when treated with any of the compounds. In the MCF7 cell line, treatment with 3 produces similar results to those of HCC1806 cell line, but treatment with 9b reduces total protein content to 15.4±9.4%. The reduction of protein content showed statistical significance in all conditions of treatment in both cell lines (p<0.001). SRB assay allows us to conclude that cell mass is significantly reduced with treatment, which indicates that cell viability is also significantly reduced.
PT induce cell death preferentially by late apoptosis and necrosis
In view of the high cytotoxicity exhibited against MCF7 and HCC1806 by 1H,3H-pyrrolo to the aggressive phenotype due to cumulative genetic alteration [7] .
On the other hand, MCF7 cell line expresses the wild-type p53 [7] , which could explain the duality of response to treatment in the clonogenic assay and viability and types of cell death. That is, cell viability is reduced to about 55/60% when both cell lines are treated with 3 and also late apoptotic/necrotic and necrotic populations are significantly increased which means that the response to treatment is probably p53 independent. However, when cells are treated with 9b their response is very distinct. MCF7 viability is significantly reduced to 21.4±4.2% and the apoptotic population is significantly increased, although with time cells are able to recover as observed with the clonogenic assay, which means that, initialy the majority of cells are affected and die but the remaining cells are able to recover after treatment. On the other hand HCC1806 is more resistant to cell death and clearly cell death through apoptosis is compromised since cell death is mainly necrotic with both treatments but its long-term survival is significantly reduced to 1.4±0.3%.
p53 Expression is influenced by 1H,3H-pyrrolo[1,2-c]thiazole 3
Although the p53 profile of the two cell lines is known, we confirmed that the HCC1806 cell line lacks its expression. Nevertheless we evaluated p53 expression by western blot to access this protein in the MCF7 cell line in response to treatment.
As we can observe in Figure 5 , p53 is increased with treatment in the MCF7 cell line, with a significant effect with 9b treatment (p<0.009). This result corroborates the increasing of the apoptotic population after 9b treatment, and the slight non significant increase of p53 expression compared to control, after 3 treatment, explains why cell death is not related to apoptosis.
1H,3H-Pyrrolo[1,2-c]thiazole increases Bax/Bcl-2 ratio
We also assessed the ratio of the expression of Bax, a pro-apoptotic protein, and Bcl-2, an antiapoptotic protein, two proteins involved in the apoptotic cell death ( Figure 6 ). Briefly, this pathway is mainly activated in response to DNA damage, which can activate p53 resulting in the expression of Bax and repression of BCl-2 proteins. Later, Bax leads to the cytochrome c release from mitochondria and later caspase activation, ultimately causing cell death by apoptosis [7, 8] .
Comparing to the control, the ratio Bax/Bcl-2 is increased in all treatments, however only treatment with 9b increase this ratio with statistical significance (MCF7: p=0.003; HCC1806:
p<0.001). As we can observe Bax/Bcl-2 ratio in the MCF7 cell line is consistent with results of cell death and p53 expression, where only treatment with 9b was able to induce a significant increase in the apoptotic cell population.
Despite the fact that HCC1806 cell line does not express p53, the Bax/Bcl-2 ratio is significantly increased with 9b treatment. This might have to do with the default Bax activation when antiapoptotic proteins such as Bcl-2 are neutralized or their expression is diminished [9] . However cell death is mainly necrotic, which means that other mechanisms of cell death might be predominant.
For instance, poly(ADP-ribose)polymerase-1 (PARP-1) promotes cell death by apoptosis when DNA damage is moderate and cell death by necrosis in the presence of extensive DNA damage, but also the balance between apoptosis and necrosis is dependent of the cell type [10] . With that in mind 1H,3H-pyrrolo[1,2-c]thiazole 3 could cause severe DNA damage and activate PARP-1 causing necrotic cell death, and also HCC1806 cell line could be more sensitive to the activation of this protein since both treatments cause necrotic cell death.
1H,3H-Pyrrolo[1,2-c]thiazole blocks cell-cycle progression preferentially at S phase
The growing evidence that these compounds could induce DNA damage led to the analysis the progress/blockade of cell cycle of MCF7 and HCC1806 cell lines after treatment with 3 and 9b. In the MCF7 cell line, both 3 and 9b, as represented in Figure 7 , decreased population of cells in the G0/G1 (3 and 9b: p<0.001) and increased cell population in the S phase (3 and 9b: p<0.001). A blockade in the G 2 /M phases is induced by compound 3 (p=0.001) but not by 9b (p>0.05). Both intra-S [11] and the G 2 /M [12] checkpoints are mostly related to stalled replication forks that can derived from DNA inter-strand crosslinks. When this particular type of DNA damage is detected, ataxia telangiectasia and Rad3 related (ATR) is activated and promotes mainly checkpoint protein kinase 1 (Chk1) phosphorylation [12] , a protein responsible for the intra-S phase arrest in order to promote DNA repair [11] . Also, Chk1-P is able to activate p53 protein, upregulating p21 WAF1 which inhibit the cyclin-dependent kinase 1-cyclin B complex (Cdk1-cyclin B) and cause cell cycle G 2 /M phase arrest [12] .
As can be observed in Figure 7 , 3 induces a blockade in the G0/G1 phase in HCC1806 cell line (p=0.001), but has no effect in the other phases of the cell cycle, indicating a state of quiescence where cells stop dividing [13] . Similarly to treatment in the MCF7 cell line, 9b produced a decreased population of HCC1806 cells in the G0/G1 (p<0.001) and an accentuated accumulation of cells in the S phase (p<0.001) and in the pre-G0 phase (p=0.011). These results indicate DNA degradation and intra-S phase arrest with the objective to promote DNA repair [11] as previously explained.
Comet Assay in the MCF7 and HCC1806 cell lines
Because of the chemical structure of the compounds it was proposed that they could be able to act by mono and bis-alkylation of DNA. The alkaline comet assay (pH>13) allows to detect DNA damage in individual eukaryotic cells, namely, single strand breaks, double strand breaks, alkaline labile sites, and transient repair sites [14] . As can be observed in Figure 8 , cells treated with IC 50 and with three times more this concentration do not show evidence of DNA breaks, in contrast with the positive controls with hydrogen peroxide. In fact, cells from treatment have the same appearance as the negative controls. However, we cannot exclude the possibility of intrastranded or interstranded crosslinking formation. Interstranded crosslinking is also a cytotoxic form of DNA damage once DNA strands separation is prevented and DNA replication is blocked. Concerning comet assay the presence of crosslinks results in less DNA migration [15] .
Conclusion
Herein, in the continuation of our series of studies on the hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles as anticancer agents against breast cancer, we introduce the potential of these compounds also for the triple-negative breast cancer, the most challenging tumors in clinical practice.
The study allowed us to redraw some conclusions regarding structure-activity relationships. Thus, the results of the in vitro activity have demonstrated that the presence of methyl groups at C-1 in the 1H,3H-pyrrolo[1,2-c]thiazole ring system is prejudicial for their activity, in all cell lines studied. The presence of a hydroxyphenyl group at C-3 seems to improve the anti-cancer activity for the TN cell line. These results, together with our previous ones, indicate that there is a differential anti-cancer activity concerning the biochemical profile of the cell lines, therefore future modifications must be envisioned taking this into account.
Furthermore, it is the first time that cellular effects beyond cytotoxicity are explored adding a new and valuable role in the screening of our compounds, giving a first insight into their mechanism of action. Both cell lines are sensitive to 3 and 9b being the TN cell line HCC1806 survival the most affected/reduced. Viability is also decreased and cell death related proteins p53, Bax and Bcl-2 are significantly altered, occurring cell cycle blockage mainly in S-phase and cell death mostly by late apoptosis and necrosis. The reported results indicate that the studied compounds may induce DNA damage.
Our studies in this family of compounds consolidate the potential of hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles for the therapy of breast cancer, particularly the triple-negative, an asset to continue with pre-clinic studies. [5] were prepared as described in the literature.
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Experimental Section
General procedure for the synthesis of 1,3-thiazolidine-4-carboxylic acids 7
A solution of the appropriate aldehyde (40.0 mmol) in ethanol (30 mL) was added to a solution of L-cysteine (5.0 g, 40.0 mmol) in water (40 mL). After stirring overnight at room temperature the product was filtered and washed with diethyl ether. 
2-(4-Methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid (7a
General procedure for the synthesis of 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole carboxylates 9 and 12
A solution of the appropriate 5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-carboxylate 8 or 11 (2.9 mmol) in dry dichloromethane (30 mL) was added dropwise to a suspension of lithium aluminium hydride (2.2 eq., 0.24 g, 6.4 mmol) in anhydrous diethyl ether (40 mL) at 0 ºC. The solution was refluxed for 1.5 h after the addition was completed and then cooled on an ice bath. The excess of hydride was carefully decomposed by addition of ethyl acetate followed by slow addition of water (0.3 mL), NaOH 15% (0.3 mL) and water (0.9 mL). The mixture was filtered through celite and the inorganic residue was washed with several portions of hot dichloromethane. The filtrate was dried (Na 2 SO 4 ) and the solvent evaporated off. The crude product was purified by flash chromatography [hexane-ethyl acetate] or recrystallization.
For the synthesis of compound 8b 3.3 equivalents of lithium aluminium hydride (0.36 g, 9.6 mmol) were used. In this case the excess of hydride was eliminated by the addition of ethyl acetate followed by slow addition of water (0.4 mL), NaOH 15% (0.4 mL) and water (1.2 mL).
(3R)-6,7-Bis(hydroxymethyl)-3-(4-methoxyphenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole (9a).
Recrystallization with diethyl ether gave 9a as a white solid (0.52 g, 58% 
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(3R)-6,7-Bis(hydroxymethyl)-3-(4-hydroxyphenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole (9b).
Recrystallization with diethyl ether gave 9b as a pale brown solid (0.43 g, 52%); mp > 220 ºC ( 
(3S)-6,7-Bis(hydroxymethyl)-1,1,5-trimethyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole (12).
Purification [α] D 20 = -205 (c 1, CH 2 Cl 2 ).
Biological evaluation 4.2.1 Cell culture
Human breast carcinoma cell lines HCC1954 and HCC1806 were cultured in RPMI-1640 medium (Sigma Aldrich®, EUA) supplemented with 10% and 5% of fetal bovine serum (FBS) (Sigma Aldrich®, EUA), respectively, 2.5 g.L -1 of D-(+)-glucose (Sigma Aldrich®, EUA), 400 mM of sodium pyruvate (Gibco®, UK), 100 U.mL -1 of penicillin and 100 U.mL -1 of streptomycin (Gibco®, UK), under an atmosphere containing 5% CO 2 at 37 ºC. Human breast adenocarcinoma cell line MCF7 was cultured in DMEM (Sigma Aldrich®, EUA) supplemented with 10% of FBS, 100 mM of sodium pyruvate, 100 U.mL -1 of penicillin and 100 U.mL -1 of streptomycin, under an atmosphere containing 5% CO 2 at 37 ºC.
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Cytotoxicity
The cells were plated in 96-well culture plates at a density of 2x10 4 
Clonogenic assay
For the clonogenic assay cells were plated in 6-well culture plates at a density of 5x10 5 cells per well and incubated to allow cell attachment. Incubation with the IC 50 of 3 or 9b was made for 48 h.
Cells were harvested, counted and 1000, 3000 or 5000 cells were plated. After 12 days, cells were fixed with methanol, stained with crystal violet and individual colonies were counted.
Sulphorhodamine B assay
For total protein production evaluation, cells were plated in 24-well culture plates at a density of 4x10 4 cells per well and incubated overnight to allow cell attachment. Cell cultures were incubated with IC 50 concentrations of the compounds 3 and 9b for 48 h (final DMSO concentration 1%). SRB assay was performed as described [19] . Briefly, cells were washed with ultra-pure water and twice with PBS. Cells were then incubated with 1% acetic acid in methanol for 30 minutes prior to incubation with 0.4% SRB (Sigma Aldrich®, EUA) dissolved in 1% acetic acid (Sigma Aldrich®, EUA) in methanol (Sigma Aldrich®, EUA) for 1 h in the dark. After incubation SRB crystals were dissolved in 10 mM Tris-NaOH, pH 10.
Cell viability and types of cell death
For analysis of cell viability and types of cell death, 2x10 6 400 µL PBS were added and samples were analysed in a FACSCalibur cytometer (BD Biosciences, EUA). Excitation was set at 488 nm, and the emission filters were set at for An-V-FITC and propidium iodide, respectively.
P53 expression
Western Blot was used to evaluate the expression of p53 protein. Cells were treated with the IC 50 of 3 or 9b during 48 h. Total protein extracts were prepared on ice using a solution of radioimmuno precipitation assay (RIPA) buffer supplemented with cOmplete Mini (Roche). After sonication and centrifugation at 14000 g, the samples were kept at -80 ºC prior use. Protein content was determined by bicinchoninic (BCA) method. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was held using a 10% acrylmide gel for 20 min at 80 V followed by 160 V till 1h 10min.
Subsequently proteins were electrotransfered to nitrocellulose (PVDF) membranes at 100 V during 1 hour. Blocking of PVDF membranes was performed with 4% bovine serum albumin (BSA) in trisbuffered saline tween-20 (TBS-T) for 1 hour at room temperature with stirring. Incubation with primary antibodies, Actin (Sigma-Aldrich) and p53 (mouse anti-human p53-DO7, Santa Cruz Biotechnology, Inc.) was performed overnight at 4ºC. After several washes with TBS-T, membranes were incubated with secondary antibody (anti-mouse antibody) for 1 hour at room temperature. New washes were performed and ultimately the blots were stained with fluorescent reagent elemental chlorine free (ECF) and reading was performed in 9000 Typhoon FLA equipment. Quantification of fluorescence was performed using the ImageQuant Software (GE Healthare).
Bax/Bcl-2 analysis
Bax and Bcl-2 expression was also analysed by flow cytometry using monoclonal antibodies conjugated with phycoerythrin (PE) and FITC respectively. Briefly, 2x10 6 cells were incubated overnight to allow cell attachment and were treated with IC 50 of 3 or 9b for 48 h (DMSO 0.1%).
Cells were collected, centrifuged and washed with PBS prior to incubation with permeabilizing solution (Intracell Kit, Immunostep), 3 µL Bax-PE (Santa Cruz Biotechnology, Inc.) and 3 µL Bcl-2-FITC (Santa Cruz Biotechnology, Inc.), for 15 minutes in the dark. After washing with PBS, analysis was performed in the FACSCalibur cytometer with excitation at 488 nm, and emission filter at 530/30 and 585/42 for BCl-2 and Bax, respectively.
Cell cycle analysis
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For analysis of DNA content, 2x10 6 
Comet assay
Damage in cell DNA were analysed with alkaline single-cell gel electrophoresis, comet assay [20] .
Briefly, 5x10 5 and MCF7 cell lines given in Table 1 
2.
1 H NMR spectra for all new compounds ( 13 C NMR spectra for compounds 9 and 12) M A N U S C R I P T
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IC 50 and confidence intervals for compounds 3, 6, 9 and 12 against HCC1806, HCCC1954 and MCF7 cell lines Figure S10. 13 C NMR spectrum of compound 12 (100 MHz, CDCl 3 ).
